Duopharma Biotech Berhad (KLSE:DPHARMA)
Malaysia · Delayed Price · Currency is MYR 1.230
+0.020 (1.65%)
At close: Jun 10, 2026
Duopharma Biotech Berhad Cash Flow Statement
Financials in millions MYR. Fiscal year is January - December.
Millions MYR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 92.54 | 87.46 | 62.65 | 52.65 | 70.11 | 65.68 |
Depreciation & Amortization | 40.45 | 40.68 | 40.58 | 38.76 | 33.48 | 29.66 |
Other Amortization | 4.83 | 4.83 | 4.81 | 4.29 | 2.72 | 2.29 |
Loss (Gain) From Sale of Assets | -0.01 | -0.01 | -0.39 | - | - | 0.01 |
Asset Writedown & Restructuring Costs | 9.52 | 9.52 | 0.02 | 2.43 | - | 0.1 |
Provision & Write-off of Bad Debts | -0.57 | -0.53 | -1.43 | 4.1 | -0.49 | 0.1 |
Other Operating Activities | 24.56 | 21.07 | 11.44 | -7.11 | 22.74 | 7.29 |
Change in Accounts Receivable | -16.04 | -28.87 | -46.6 | -5.81 | -13.28 | -4.14 |
Change in Inventory | -65.37 | -60.67 | -15.35 | -12.39 | -53.36 | -78.43 |
Change in Accounts Payable | 9.15 | 33.36 | 27.62 | -28.1 | 8.35 | 20.64 |
Operating Cash Flow | 99.06 | 106.83 | 83.34 | 48.8 | 70.27 | 43.2 |
Operating Cash Flow Growth | -13.31% | 28.18% | 70.77% | -30.54% | 62.63% | -39.45% |
Capital Expenditures | -25.19 | -26.84 | -23.57 | -32.95 | -65.18 | -109.36 |
Sale of Property, Plant & Equipment | 0.21 | 0.21 | 0.5 | - | - | 0.02 |
Sale (Purchase) of Intangibles | -6.14 | -6.34 | -10.32 | -6.61 | -5.84 | -5.64 |
Investment in Securities | - | - | - | -6.42 | - | -2.07 |
Other Investing Activities | 6.06 | 5.87 | 5.97 | 2.75 | 1.52 | 1.2 |
Investing Cash Flow | -25.06 | -27.1 | -27.43 | -43.23 | -69.5 | -115.86 |
Long-Term Debt Issued | - | 58.15 | 93.37 | 486.35 | 85.67 | 186.78 |
Long-Term Debt Repaid | - | -78.75 | -128.87 | -369.97 | -59.27 | -89.46 |
Net Debt Issued (Repaid) | -19.73 | -20.6 | -35.5 | 116.37 | 26.4 | 97.33 |
Common Dividends Paid | -43.77 | -33.67 | -26.93 | -8.85 | -8.2 | -44.96 |
Financing Cash Flow | -63.5 | -54.27 | -62.43 | 107.52 | 18.2 | 52.37 |
Foreign Exchange Rate Adjustments | 1.31 | 0.87 | 0.56 | -0.23 | 0.69 | 0.24 |
Net Cash Flow | 11.81 | 26.33 | -5.96 | 112.87 | 19.66 | -20.05 |
Free Cash Flow | 73.87 | 79.99 | 59.77 | 15.86 | 5.08 | -66.16 |
Free Cash Flow Growth | -15.57% | 33.83% | 276.91% | 211.98% | - | - |
Free Cash Flow Margin | 8.06% | 8.59% | 7.35% | 2.25% | 0.73% | -10.35% |
Free Cash Flow Per Share | 0.08 | 0.08 | 0.06 | 0.02 | 0.01 | -0.07 |
Cash Interest Paid | 23.87 | 24.52 | 27.02 | 21.71 | 16.54 | 11.97 |
Cash Income Tax Paid | 11.91 | 17.42 | 10.66 | 16.83 | 24.51 | 11.66 |
Levered Free Cash Flow | 49.3 | 50.92 | 31.95 | -10.33 | -6.71 | -60.93 |
Unlevered Free Cash Flow | 64 | 66.02 | 48.05 | 0.72 | -1.02 | -56.91 |
Change in Working Capital | -72.26 | -56.19 | -34.32 | -46.3 | -58.29 | -61.93 |